ALNYAlnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2026 on Thursday, July 30, 2026, before the U.S. financial markets open. Management will provide an update on the Company...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today shared advances across its growing neuroscience portfolio at the Alzheimers Association International Conference (AAIC) 2026. This scientific progress underscores the potential of RNAi therapeutics to address...

AstraZeneca and Ionis announced on Thursday that their late-stage CARDIO-TTRansform trial for eplontersen (Wainua) failed to meet its main goal.

In early trading on Thursday, shares of Alnylam Pharmaceuticals topped the list of the day's best performing components of the Nasdaq 100 index, trading up 15.4%. Year to date, Alnylam Pharmaceuticals has lost about 6.1% of its value. And the worst performing Nasdaq 100 compon...

AZN shares tumble after Wainua missed the primary endpoint in a late-stage ATTR-CM study, raising questions about its expansion into a larger market.

Gainers Virax Biolabs Group (NASDAQ:VRAX) stock increased by 134.0% to $7.44 during Thursday's pre-market session. The company's market cap stands at $2.5 million. Alnylam Pharmaceuticals (NASDAQ:ALNY) stockread more...

ALNY's advancing pipeline and partnered programs can expand future revenue sources alongside its growing portfolio of approved therapies.

Regeneron's cemdisiran won FDA Priority Review and EMA filing acceptance for gMG, backed by phase III data and a potentially unique dosing schedule.

Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 10 years by 3.79% on an annualized basis producing an average annual return of 17.65%. Currently, Alnylam Pharmaceuticals has a marketread more...